Sionna Therapeutics, Inc. Common Stock
SIONSionna Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies targeting cell signaling pathways involved in oncology and other diseases. Leveraging advanced scientific research, the company aims to create novel treatments that address unmet medical needs in cancer and related conditions.
Company News
Sionna Therapeutics, a clinical-stage biopharmaceutical company focused on cystic fibrosis treatment, announced its participation in two major investor conferences in June 2026: the Jefferies Global Healthcare Conference on June 3rd and the Goldman Sachs 47th Annual Global Healthcare Conference on June 10th. The company is developing novel medici...
Sionna Therapeutics, a clinical-stage biopharmaceutical company focused on cystic fibrosis treatment, announced that management will participate in a fireside chat at the 2026 RBC Capital Markets Global Healthcare Conference on May 20th, 2026. The company is developing novel medicines targeting the CFTR protein, with a focus on NBD1 stabilizers t...
A director of Sionna Therapeutics sold $2.5 million in shares (55,345 shares at $44.67 each) through OrbiMed Private Investments VIII, LP on April 17-18, 2026. Despite the 215% one-year stock surge, the sale represents only 2% of the related party's indirect holdings and reflects normal portfolio trimming. The biotech company is positioned well f...
Sionna Therapeutics' Chief Legal Officer Jennifer Fitzpatrick exercised and immediately sold 10,250 shares on March 5, 2026, generating approximately $347,000 in proceeds. The sale represented 100% of her direct common stock holdings, though she retains 50,935 options. The transaction was pre-scheduled under a 10b5-1 plan adopted in June 2025, su...
OrbiMed Advisors sold 33,356 shares of Sionna Therapeutics for approximately $1.5 million on December 24, 2025, reducing its indirect holdings to 3.56 million shares. The sale represents a routine disposition as part of structured block sales, not an indication of insider concern. Sionna, a clinical-stage biotech focused on cystic fibrosis treatm...
